2-(1H-benzimidazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile | 281224-16-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1H-benzimidazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile
• 英文别名: 2-(1H-benzo[d]imidazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile；2-(1H-benzimidazol-2-yl)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile
• CAS: 281224-16-6
• 化学式: C₁₈H₁₅N₃O₂
• mdl: MFCD00392762
• 分子量: 305.336
• InChiKey: SIPOTHFKLAFEAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  70.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1H-benzimidazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile 在 苄基三乙基氯化铵 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 乙醇 、 氯仿 、 乙腈 为溶剂， 反应 5.5h， 生成 3-(3,4-Dimethoxyphenyl)-2-(1-methylbenzimidazol-2-yl)propanenitrile
  参考文献：
  名称：

  Unexpected Regiospecific Reduction of the Double Bond by NaBH₄ in 2‐(1‐Methyl/1H‐benzimidazole‐2‐yl)‐3‐aryl‐acrylonitrile

  摘要：

  Condensation of (1H-benzimidazole-2-yl)-acetonitrile 1 with aromatic aldehydes in 5% NaOH solution gave the corresponding 2-(1H-benzimidazole-2-yl)3-aryl-acrylonitrile 2, which on treatment with NaBH4 in ethanol unexpectedly gave 2-(1H-benzimidazole-2-yl)-3-aryl-propionitrile 3 by the regiospecific reduction of the double bond. Shaking a solution of 2 with H-2/Pd-C in methanol also gave 3. Reaction of 2 with DMS gave the corresponding N-methylated analogue 5, which also with NaBH4 gave 6, once again by the regiospecific reduction of the double bond as in the case of 1-demethylated analogue ( i. e., 2).

  DOI：

  10.1080/00397910701397177
• 作为产物：
  描述：

  邻苯二胺 在 哌嗪 作用下， 以 乙醇 为溶剂， 反应 4.5h， 生成 2-(1H-benzimidazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile
  参考文献：
  名称：

  Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein

  摘要：

  Human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, MG) is a potent restriction factor against human immunodeficiency virus type 1 (HIV-1) by inducing hypermutation of G to A in viral genome after its incorporation into virions. HIV-1 Vif (Virion Infectivity Factor) counteracts A3G by inducing ubiquitination and proteasomal degradation of MG protein. Vif-A3G axis therefore is a promising therapeutic target of HIV-1. Here we report the screening, synthesis and SAR studies of benzimidazole derivatives as potent inhibitors against HIV-1 replication via protecting MG protein. Based on the steep SAR of the benzimidazole scaffold, we identified compound 14 and 26 which provided the best potency, with IC50 values of 3.45 nM and 58.03 nM respectively in the anti-HIV-1 replication assay in H9 cells. Compound 14 and 26 also afforded protective effects on MG protein level. Both compounds have been proved to be safe in acute toxicological studies. Taken together, we suggest that these two benzimidazole derivatives can be further developed as a new category of anti-HIV-1 leads. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.050

文献信息

• Ionic tagged amine supported on magnetic nanoparticles: synthesis and application for versatile catalytic Knoevenagel condensation in water
  作者：Anguo Ying、Fangli Qiu、Chenglin Wu、Huanan Hu、Jianguo Yang

  DOI：10.1039/c4ra05540c

  日期：——

  Propylamine modified with imidazolium ionic moiety grafted onto magnetic nanoparticles (MNPs) was prepared and evaluated as a catalyst for Knoevenagel condensation in water at room temperature. The catalyst was efficient in the reaction to give the condensation products in good yields. It is worth noting that the ionic-tagged catalyst performed significantly better than its ionic tag-free counterpart

  制备了用咪唑鎓离子部分改性的丙胺，将其接枝到磁性纳米颗粒（MNP）上，并作为室温下水中Knoevenagel缩合的催化剂进行了评估。该催化剂在反应中有效，以高收率得到缩合产物。值得注意的是，带有离子标记的催化剂的性能明显优于不含离子标记的催化剂。最后，该催化剂可重复使用8次，但催化活性略有下降。
• Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors
  作者：Bing Li、Steven C. Cardinale、Michelle M. Butler、Ramdas Pai、Jonathan E. Nuss、Norton P. Peet、Sina Bavari、Terry L. Bowlin

  DOI：10.1016/j.bmc.2011.10.062

  日期：2011.12

  Botulinum neurotoxins (BoNTs) are the most lethal of biological substances, and are categorized as class A biothreat agents by the Centers for Disease Control and Prevention. There are currently no drugs to treat the deadly flaccid paralysis resulting from BoNT intoxication. Among the seven BoNT serotypes, the development of therapeutics to counter BoNT/A is a priority (due to its long half-life in the neuronal cytosol and its ease of production). In this regard, the BoNT/A enzyme light chain (LC) component, a zinc metalloprotease responsible for the intracellular cleavage of synaptosomal-associated protein of 25 kDa, is a desirable target for developing post-BoNT/A intoxication rescue therapeutics. In an earlier study, we reported the high throughput screening of a library containing 70,000 compounds, and uncovered a novel class of benzimidazole acrylonitrile-based BoNT/A LC inhibitors. Herein, we present both structure-activity relationships and a proposed mechanism of action for this novel inhibitor chemotype. (C) 2011 Elsevier Ltd. All rights reserved.
• Unexpected Regiospecific Reduction of the Double Bond by NaBH₄ in 2‐(1‐Methyl/1H‐benzimidazole‐2‐yl)‐3‐aryl‐acrylonitrile
  作者：P. K. Dubey、P. V. V. Prasada Reddy

  DOI：10.1080/00397910701397177

  日期：2007.7.1

  Condensation of (1H-benzimidazole-2-yl)-acetonitrile 1 with aromatic aldehydes in 5% NaOH solution gave the corresponding 2-(1H-benzimidazole-2-yl)3-aryl-acrylonitrile 2, which on treatment with NaBH4 in ethanol unexpectedly gave 2-(1H-benzimidazole-2-yl)-3-aryl-propionitrile 3 by the regiospecific reduction of the double bond. Shaking a solution of 2 with H-2/Pd-C in methanol also gave 3. Reaction of 2 with DMS gave the corresponding N-methylated analogue 5, which also with NaBH4 gave 6, once again by the regiospecific reduction of the double bond as in the case of 1-demethylated analogue ( i. e., 2).
• Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein
  作者：Ting Pan、Xin He、Bing Chen、Hui Chen、Guannan Geng、Haihua Luo、Hui Zhang、Chuan Bai

  DOI：10.1016/j.ejmech.2015.03.050

  日期：2015.5

  Human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, MG) is a potent restriction factor against human immunodeficiency virus type 1 (HIV-1) by inducing hypermutation of G to A in viral genome after its incorporation into virions. HIV-1 Vif (Virion Infectivity Factor) counteracts A3G by inducing ubiquitination and proteasomal degradation of MG protein. Vif-A3G axis therefore is a promising therapeutic target of HIV-1. Here we report the screening, synthesis and SAR studies of benzimidazole derivatives as potent inhibitors against HIV-1 replication via protecting MG protein. Based on the steep SAR of the benzimidazole scaffold, we identified compound 14 and 26 which provided the best potency, with IC50 values of 3.45 nM and 58.03 nM respectively in the anti-HIV-1 replication assay in H9 cells. Compound 14 and 26 also afforded protective effects on MG protein level. Both compounds have been proved to be safe in acute toxicological studies. Taken together, we suggest that these two benzimidazole derivatives can be further developed as a new category of anti-HIV-1 leads. (C) 2015 Elsevier Masson SAS. All rights reserved.